RT
Rebecca Taub, M.D.
Founder and Director, Senior Scientific and Medical Advisor
Madrigal PharmaceuticalsTherapeutic Areas
Madrigal Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Resmetirom | MASH with moderate to advanced fibrosis (F2-F3) | Approved |
| Ervogastat combination | MASH | Phase 2 |
| MGL-2086 | Undisclosed | Phase 1 |
Leadership Team at Madrigal Pharmaceuticals
BS
Bill Sibold
Chief Executive Officer and Director
DS
David Soergel, M.D.
Executive Vice President, Chief Medical Officer